Alpha Cognition Inc. (NASDAQ:ACOG) Stock Short Interest Climbs 54.6%

Posted by Brian Himes on Oct 17th, 2026

Alpha Cognition Inc. (NASDAQ:ACOG – Get Free Report) saw a large increase in short interest in September. As of September 30th, there was short interest totaling 323,405 shares, an increase of 54.6% from the September 15th total of 209,226 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 115,854 shares, the short-interest ratio is presently 2.8 days.

Insiders Place Their Bets

In other news, Director Robert Wills bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was bought at an average price of $9.62 per share, for a total transaction of $96,200.00. Following the transaction, the director directly owned 32,241 shares of the company’s stock, valued at $310,158.42. This represents a 44.96% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 8.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Opaleye Management Inc. increased its stake in shares of Alpha Cognition by 13.0% in the second quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company’s stock worth $20,905,000 after buying an additional 333,517 shares during the period. AWM Investment Company Inc. purchased a new stake in Alpha Cognition during the 2nd quarter valued at $12,073,000. Aristides Capital LLC boosted its position in Alpha Cognition by 1.4% during the 1st quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock valued at $1,200,000 after buying an additional 3,052 shares during the period. Finally, ACT Capital Management LLC purchased a new stake in Alpha Cognition during the 4th quarter valued at $335,000.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ACOG. Craig Hallum reiterated a “buy” rating and set a $17.00 price target on shares of Alpha Cognition in a research report on Friday, August 14th. Raymond James Financial started coverage on shares of Alpha Cognition in a research note on Friday, July 10th. They issued an “outperform” rating and a $20.00 price objective for the company. Wall Street Zen raised shares of Alpha Cognition from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright increased their target price on shares of Alpha Cognition from $18.00 to $20.00 and gave the company a “buy” rating in a report on Monday, August 17th. Finally, B. Riley Financial assumed coverage on shares of Alpha Cognition in a research report on Thursday, August 20th. They issued a “buy” rating and a $21.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $18.00.

View Our Latest Research Report on ACOG

Alpha Cognition Stock Down 3.1%

Shares of NASDAQ ACOG traded down $0.26 during midday trading on Friday, reaching $8.19. The company had a trading volume of 70,409 shares, compared to its average volume of 96,161. The stock has a market cap of $178.38 million, a PE ratio of -7.45 and a beta of 2.32. Alpha Cognition has a one year low of $4.50 and a one year high of $10.14. The firm’s fifty day moving average price is $8.99 and its 200-day moving average price is $7.61.

Alpha Cognition (NASDAQ:ACOG – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.01). The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $4.38 million. Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%. As a group, equities research analysts expect that Alpha Cognition will post -1.38 EPS for the current year.

Alpha Cognition Company Profile

(Get Free Report)

Alpha Cognition Inc (NASDAQ: ACOG) is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative disorders, including Alzheimer’s disease and related cognitive conditions. The company’s work is centered on addressing unmet needs in the diagnosis, management and treatment of diseases that affect memory and cognitive function.

Its lead commercial product is ZUNOVO (memantine hydrochloride extended-release capsules), a prescription therapy approved by the U.S.